CTLA-4 Blockade Resistance after Relatlimab and Nivolumab - Menzies, Alexander M; Pires da Silva, Ines; Trojaniello, Claudia; Vieu, Elisabeth; Amaria, Rodabe N; Zimmer, Lisa; Lo, Serigne N; Burton, Elizabeth M; Tawbi, Hussein A; Schadendorf, Dirk; Grob, Jean J; Ascierto, Paolo A; et al. (The New England journal of medicine, 2022)
Keywords: Antibodies; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Antigens; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Agents, Immunological - therapeutic use; CD223 antigen; Confidence intervals; Cross-resistance; CTLA-4 Antigen - antagonists & inhibitors; CTLA-4 protein; Cytotoxicity; Dermatology; Drug Resistance; Drug Resistance, Neoplasm; Hematology; Humans; Immune checkpoint inhibitors; Immune Checkpoint Inhibitors - adverse effects; Immune Checkpoint Inhibitors - therapeutic use; Immunotherapy; Lymphocytes; Melanoma; Metastases; Nivolumab - adverse effects; Nivolumab - therapeutic use; Oncology; PD-1 protein; Skin Cancer; Treatments in Oncology; Tumors